<SEC-DOCUMENT>0001140361-24-034440.txt : 20240726
<SEC-HEADER>0001140361-24-034440.hdr.sgml : 20240726
<ACCEPTANCE-DATETIME>20240726171540
ACCESSION NUMBER:		0001140361-24-034440
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20240724
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240726
DATE AS OF CHANGE:		20240726

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADMA BIOLOGICS, INC.
		CENTRAL INDEX KEY:			0001368514
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				562590442
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36728
		FILM NUMBER:		241148057

	BUSINESS ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446
		BUSINESS PHONE:		(201) 478-5552

	MAIL ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	R&R ACQUISITION VI, INC
		DATE OF NAME CHANGE:	20060707
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ef20033085_8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:cef="http://xbrl.sec.gov/cef/2023" xmlns:adma="http://admabiologics.com/20240724" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.6.1.5240
         Copyright 1995 - 2024 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; background-color: #ffffff;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_edfc46eeb3c447a49242924b28ef2677" contextRef="c20240724to20240724" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_5c1a15279b7d4929bdbc1be3135768a2" contextRef="c20240724to20240724">0001368514</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="adma-20240724.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20240724to20240724"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-24</xbrli:startDate><xbrli:endDate>2024-07-24</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
<div style="line-height: initial;">
  <div><span style="font-size: 10pt;"> </span></div>

  <hr style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
  <div>
    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">UNITED STATES</div>

    <div><span style="font-size: 14pt;"> </span></div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 14pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">Washington, D.C. 20549</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 18pt; font-weight: bold;">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_1ef4e8fd317e4c2682688087f5119158" contextRef="c20240724to20240724">8-K</ix:nonNumeric></div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">CURRENT REPORT</div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Date of Report (Date of earliest event reported): <span style="text-decoration: underline;"><ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_dc63f37d317c4e6c934201738b484ecb" contextRef="c20240724to20240724" format="ixt:date-monthname-day-year-en">July 24, 2024</ix:nonNumeric></span></div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 100%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-weight: bold;"><span style="font-size: 24pt;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_c8703c5d637e4943b13d343620a1c23b" contextRef="c20240724to20240724">ADMA BIOLOGICS, INC.</ix:nonNumeric></span><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 100%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">(Exact name of registrant as specified in its charter)</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 33.33%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt; text-align: center;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_c100646f88be4590a9401605ec91a21d" contextRef="c20240724to20240724" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric><br/>
          </td>

    <td style="width: 34%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_e8ace964bebb4a18adb852d8ae6751c8" contextRef="c20240724to20240724">001-36728</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 33.32%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_607999d3dd13480785d070450ea7641d" contextRef="c20240724to20240724">56-2590442</ix:nonNumeric><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td style="width: 33.33%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(State or other jurisdiction of incorporation)</div>
          </td>

    <td style="width: 34%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(Commission File Number)</div>
          </td>

    <td style="width: 33.32%; vertical-align: bottom;">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(IRS Employer Identification No.)</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 49%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_3a9f1bc68ee74cab82a0a832327366a8" contextRef="c20240724to20240724">465 State Route 17</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_b989b2d05f2246889dd92ae418ee706b" contextRef="c20240724to20240724">Ramsey</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_2dd1b53878d445da8488474f5a63accd" contextRef="c20240724to20240724" format="ixt-sec:stateprovnameen">New Jersey</ix:nonNumeric></div>
          </td>

    <td style="width: 2%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="1">&#160;</td>

    <td style="width: 49%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_cb4f955045f14bbdbb5fbe0035ce95c1" contextRef="c20240724to20240724">07446</ix:nonNumeric><br/>
            </div>
          </td>

  </tr>

  <tr>

    <td rowspan="1" style="width: 49%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">(Address of principal executive offices)</div>
          </td>

    <td rowspan="1" style="width: 2%; vertical-align: bottom; font-size: 10pt;" colspan="1">&#160;</td>

    <td rowspan="1" style="width: 49%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">(Zip Code)</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Registrant&#8217;s telephone number, including area code: <span style="font-family: 'Times New Roman';"><span style="text-decoration: underline;">(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_d97ec8b141c04247b707a2ab31baa0ab" contextRef="c20240724to20240724">201</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_6e8856ba6974423e95f4280f4828d5e6" contextRef="c20240724to20240724">478-5552</ix:nonNumeric></span></span></div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 100%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 100%; vertical-align: bottom; font-size: 10pt;">
            <div style="text-align: center; font-family: 'Times New Roman';">(Former name or former address, if changed since last report.)</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<span style="font-family: 'Times New Roman'; font-style: italic;">see</span> General Instruction A.2. below):</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:WrittenCommunications" id="Fact_4090b26ae35a4df7bff0b1916773d9eb" contextRef="c20240724to20240724" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</div>
            </td>

  </tr>


</table>
    </div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:SolicitingMaterial" id="Fact_f98386a0629d4ae7bd42ca009ef7d22b" contextRef="c20240724to20240724" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</div>
            </td>

  </tr>


</table>
    </div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:PreCommencementTenderOffer" id="Fact_e0c6445f485b4993b272a3b63a29a6c8" contextRef="c20240724to20240724" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</div>
            </td>

  </tr>


</table>
    </div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div>
      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 18pt; vertical-align: top; text-align: right; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" id="Fact_1c06d2ef52674734b747a430f87cf158" contextRef="c20240724to20240724" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
              </div>
            </td>

    <td style="width: auto; vertical-align: top; font-size: 10pt;">
              <div style="text-align: left; font-family: 'Times New Roman';">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</div>
            </td>

  </tr>


</table>
    </div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">Securities registered pursuant to Section 12(b) of the Act:</div>

    <div style="font-size: 10pt;">&#160;</div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 40.35%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Title of each class</div>
          </td>

    <td style="width: 20%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Trading Symbol(s)</div>
          </td>

    <td style="width: 40.41%; vertical-align: top; border-width: 2px; border-style: solid; border-color: rgb(0, 0, 0) rgb(0, 0, 0) rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Name of each exchange on which registered</div>
          </td>

  </tr>

  <tr>

    <td style="width: 40.35%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><ix:nonNumeric name="dei:Security12bTitle" id="Fact_43a97ff69a43409e92a425a7f0c81fc6" contextRef="c20240724to20240724">Common stock, par value $0.0001 per share</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 20%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_17a93cc70757422db347cd4f1e5c9324" contextRef="c20240724to20240724">ADMA</ix:nonNumeric><br/>
            </div>
          </td>

    <td style="width: 40.41%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;">
            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman';"><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_26a7ae3d11b143f29813bc6134b4d9eb" contextRef="c20240724to20240724" format="ixt-sec:exchnameen">Nasdaq Global Market</ix:nonNumeric><br/>
            </div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or
      Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_7ad0cee0f40b44ed92ebf1abe6c6c856" contextRef="c20240724to20240724" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised
      financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> <br/>
      </span></div>

    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">
      <hr style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"/>
<div><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"> </span></div>
</div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 5.02</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="font-family: 'Times New Roman'; font-weight: bold;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Promotion of Brad Tade to Chief Financial Officer and Treasurer</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Effective July 24, 2024 (the &#8220;Effective Date&#8221;), Brad Tade, former Vice President, Financial Operations of ADMA Biologics, Inc. (the &#8220;Company&#8221;), was promoted to Chief
      Financial Officer and Treasurer of the Company (the &#8220;Promotion&#8221;).</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Mr. Tade, age 51, joined the Company in June 2023 as its Vice President, Financial Operations. Prior to joining the Company, he held roles of increasing responsibility
      at PCI Pharma Services. From March 2023 to June 2023, Mr. Tade held the position of Vice President Finance, Commercial Packaging Technology and from August 2022 to March 2023, held the position of Vice President Finance, Development and
      Manufacturing. Prior to working for PCI Pharma Services, from May 2021 to July 2022 Mr. Tade held the role of Vice President Finance, Operations &amp; Quality for Baxter International Inc. based in Illinois and from November 2016 to May 2021, served
      as Vice President, Operations Finance for Becton Dickinson based in Switzerland. Mr. Tade holds a B.S. in Finance from California State University, Long Beach and a Master&#8217;s in Organizational Leadership from Gonzaga University. There have been no
      related party transactions between the Company and Mr. Tade reportable under Item 404(a) of Regulation S-K, there are no arrangements or understandings between Mr. Tade and any other person pursuant to which he was appointed as an officer reportable
      under Item 404(b) of Regulation S-K, and Mr. Tade has no family relationships with any of our directors or executive officers reportable under Item 401(d) of Regulation S-K.</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">On the Effective Date, the Company and Mr. Tade entered into an Employment Agreement (the &#8220;Employment Agreement&#8221;), pursuant to which Mr. Tade will serve as the Chief
      Financial Officer and Treasurer of the Company. The Employment Agreement provides that the employment relationship may be terminated by either party for any reason, at any time, with or without prior notice and with or without &#8220;Cause&#8221; (as defined
      therein).</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Employment Agreement further provides, in the event (i) that Mr. Tade is terminated by the Company without Cause, (ii) that Mr. Tade resigns for &#8220;Good Reason&#8221; (as
      defined therein), or (iii) of any termination resulting from a &#8220;Change of Control&#8221; (as defined therein) in which the Employment Agreement is not assumed by the successor to the Company, he would be entitled to (in addition to any accrued but unpaid
      salary and unreimbursed expenses): (A) in the event Mr. Tade elects continued coverage under the Consolidated Omnibus Budget Reconciliation Act (COBRA), reimbursement from the Company for the same portion of Mr. Tade&#8217;s family COBRA health insurance
      premium that it paid during his employment up until the earlier of (x) the date twelve (12) months after Mr. Tade&#8217;s termination and (y) the date on which Mr. Tade is eligible for comparable health benefits with another company or business entity;
      provided, however, that in the event Mr. Tade&#8217;s employment is terminated without Cause, for Good Reason or resulting from a Change of Control in which the Employment Agreement is not assumed by the Company&#8217;s successor, and such termination
      immediately precedes, or occurs within one year following, a Change of Control, the Company will reimburse Mr. Tade for the same portion of his family COBRA health insurance premium that it paid during his employment up until the earlier of (I) the
      date twelve (12) months after the date of Mr. Tade&#8217;s termination and (II) the date on which Mr. Tade is eligible for comparable health benefits with another company or business entity; (B) any Target Bonus that has not been paid from the prior
      performance year to the extent the Board has determined in good faith that the goals have been attained; (C) a severance payment equal to&#160; twelve (12) months of base salary payable in twelve (12) monthly, equal installments after termination or, if
      such termination is immediately preceding or within one year following a Change of Control, a severance payment equal to fifteen (15) months&#8217; base salary plus one and a half (1 &#189;) times the Target Bonus payable in a lump sum, and (C) accelerated
      vesting of all stock options previously granted to Mr. Tade and all stock options granted in the future to Mr. Tade (the &#8220;Tade Stock Options&#8221;), as well as all restricted stock units previously granted to Mr. Tade and all restricted stock units
      granted in the future to Mr. Tade (the &#8220;Tade RSUs&#8221;), as described in the following sentence. If Mr. Tade is terminated without Cause or Mr. Tade resigns for Good Reason, in either case immediately preceding or within one year after a Change of
      Control, (i) such Tade Stock Options will accelerate in full and such Tade Stock Options shall remain exercisable until the earlier of eighteen (18) months after Mr. Tade&#8217;s termination of employment or the expiration of the ten (10)-year term of the
      Tade Stock Options, and (ii) all Tade RSUs granted at the time of termination to Mr. Tade shall be immediately vested. Furthermore, any payments, awards, benefits or distributions due to Mr. Tade under the Employment Agreement as a result of a
      transaction described in Section 280G may be subject to a cutback as set forth in the Employment Agreement. In the event that the Employment Agreement is terminated as a result of Mr. Tade&#8217;s death, becoming Disabled (as defined therein), material
      breach of the Employment Agreement, by the Company with Cause or if Mr. Tade resigns without Good Reason, the Company shall have no further obligations to Mr. Tade under the Employment Agreement except for the payment of Mr. Tade&#8217;s accrued, unpaid
      base salary through the termination date, any unreimbursed expenses, subject to any right of set-off and, if terminated as a result of Mr. Tade&#8217;s death or becoming Disabled, the Company will reimburse Mr. Tade (or his qualified beneficiaries) for the
      same portion of his family COBRA health insurance premium (if continued coverage under COBRA is elected) and COBRA dental and vision premiums (if available under COBRA) that it paid during Mr. Tade&#8217;s employment for at least twelve (12) months after
      the date of his termination and Mr. Tade or his estate shall be entitled to any unpaid annual bonus from any prior performance year.</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Employment Agreement also contains a mutual non-disparagement covenant and customary non-competition, non-solicitation, confidentiality and invention assignment
      covenants.</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In consideration of Mr. Tade&#8217;s entering into the Employment Agreement, on the Effective Date, Mr. Tade was granted (ii) an option to purchase 115,100 shares of common
      stock, $0.0001 par value per share, of the Company (&#8220;Common Stock&#8221;), which will vest over four years with 25% of the shares underlying the option vesting on the one-year anniversary of the Effective Date and the remaining 75% of such shares vesting
      monthly in equal installments over the next three years, becoming fully vested on the four-year anniversary of the Effective Date, and (ii) 72,400 restricted stock units, which will vest in four equal annual installments (25% per installment) on each
      anniversary of the Effective Date over four years, in each case under the ADMA Biologics, Inc. 2022 Equity Compensation Plan.</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The Employment Agreement provides that Mr. Tade is (i) entitled to a base salary of $435,000 annually, (ii) eligible for an annual cash bonus with a target equal to
      forty-five percent (45%) of Mr. Tade&#8217;s base salary (&#8220;Target Bonus&#8221;), based upon the attainment of certain performance milestones and objectives established by the Company&#8217;s Board of Directors (&#8220;Board&#8221;) (acting through the Compensation Committee) in
      consultation with Mr. Tade; and (iii) eligible to participate in the Company&#8217;s standard benefits package.</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">The foregoing summary of the Employment Agreement does not purport to be complete and is qualified in its entirety by reference to the copy of the Employment Agreement
      filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated by reference herein.</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">


  <tr>

    <td style="width: 54pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Item 9.01</td>

    <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">Exhibits</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">(d) Exhibits</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 12%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;">Exhibit No.</span></div>
          </td>

    <td style="width: 88%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;"><span style="text-decoration: underline;">Description</span></div>
          </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';"><a href="ef20033085_ex10-1.htm">10.1</a></div>
          </td>

    <td style="width: 88%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Employment Agreement, dated July 24, 2024, by and between the Company and Brad Tade.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 12%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">104</div>
          </td>

    <td style="width: 88%; vertical-align: top;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Cover Page Interactive Data File (embedded with the Inline XBRL document).</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

    </div>

    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">SIGNATURE</span></div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the
      undersigned hereunto duly authorized.</div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">


  <tr>

    <td style="width: 60%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">July 26, 2024</div>
          </td>

    <td style="vertical-align: top; font-size: 10pt;" colspan="3">
            <div style="text-align: left; font-family: 'Times New Roman';">ADMA Biologics, Inc.</div>
          </td>

  </tr>

  <tr>

    <td style="width: 60%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="vertical-align: top; font-size: 10pt;" colspan="3">&#160;</td>

  </tr>

  <tr>

    <td style="width: 60%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 3%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">By:</div>
          </td>

    <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman';">/s/ Adam S. Grossman</div>
          </td>

  </tr>

  <tr>

    <td style="width: 60%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Name:</div>
          </td>

    <td style="width: 32%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Adam S. Grossman</div>
          </td>

  </tr>

  <tr>

    <td style="width: 60%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 3%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Title:</div>
          </td>

    <td style="width: 32%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">President and Chief Executive Officer</div>
          </td>

  </tr>


</table>
    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="font-size: 10pt;"><br/>
    </div>

    <div style="font-size: 10pt;">
      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/></div>

  </div>

  <div><span style="font-size: 10pt;"> </span></div>

</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ef20033085_ex10-1.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Broadridge
         Document created using Broadridge PROfile 24.6.1.5240
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <font style="font-size: 10pt;"> </font>
  <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
  <div>
    <div style="text-align: center; color: #000000; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">
      <div style="text-align: right; font-size: 10pt;">Exhibit 10.1<br>
      </div>
      <div style="font-size: 10pt;"><br>
      </div>
      <font style="font-size: 10pt;">EMPLOYMENT AGREEMENT</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">This EMPLOYMENT AGREEMENT (this &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Agreement</font>&#8221;), dated July
      24, 2024 (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Effective Date</font>&#8221;), is entered into by and between ADMA Biologics, Inc., a Delaware corporation (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Company</font>&#8221;), and Brad Tade (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Executive</font>&#8221;).</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"><u>STATEMENT OF AGREEMENT</u></div>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zd7926a795ef24d4e8f325ab93548bf38" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 63pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Section 1.</td>
          <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"><u>EMPLOYMENT</u></div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 1.1</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Term; At-Will Employment</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Executive acknowledges and understands that employment with the Company is &#8220;at-will,&#8221; which means the employment relationship can be terminated by
      either party for no reason or for any reason not otherwise specifically prohibited by law, at any time, with or without prior notice and with or without cause except as provided herein.&#160; Nothing in this Agreement is intended to alter Executive&#8217;s
      at-will employment status or obligate the Company to continue to employ Executive for any specific period of time.&#160; Any statements or representations to the contrary should be regarded by Executive as ineffective, and any modification or change in
      Executive&#8217;s at-will employment status may only occur by way of a <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">writing signed by the parties hereto, and approved by the Board </font>(as defined below).&#160; For purposes of this
      Agreement, any reference to the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Term</font>&#8221; of this Agreement shall mean the duration of Executive&#8217;s employment with the Company.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Section 1.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Title and Duties</u></font>.&#160; During the Term, Executive shall be employed as the Chief Financial Officer and Treasurer of the Company. Executive shall report to the President and Chief Executive Officer of the Company.
          Executive shall devote substantially all of his business skill, time and effort to his employment hereunder and, other than as specifically provided for herein, shall not serve as an employee, director or consultant of any other entity without
          the consent of the Board of Directors of the Company (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Board</font>&#8221;), <font style="font-family: 'Times New Roman'; font-style: italic;">provided</font>, <font style="font-family: 'Times New Roman'; font-style: italic;">however</font>, that he shall be entitled annually to vacation and sick leave pursuant to policies adopted by the Company from time to time for executive officers of the Company.&#160; In
          addition, Executive may serve on Boards of Directors, Boards of Trustees or other similar positions for up to two company or companies (whether for profit or not for profit) at any time that do not compete with the Company and do not interfere
          with his ability to satisfy his obligations hereunder; <font style="font-family: 'Times New Roman'; font-style: italic;">provided, however,</font> that, with respect to for profit entities, such service is subject to the approval of the Board
          (or a Committee thereof), which shall not be unreasonably withheld or delayed.&#160; In addition, Executive may manage his personal financial affairs and participate in civic and charitable endeavors provided that such activities do not unreasonable
          interfere with his ability to satisfy his obligations hereunder.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Section 1.3</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><u>Place of Employment</u>.</font></font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Executive&#8217;s principal place of employment will be at the Company&#8217;s offices at 5800 Park of Commerce Boulevard NW, Boca Raton,
      Florida 33487 unless mutually agreed by the parties.&#160; The Company may, however, require Executive to reasonably travel on business to an extent consistent with Executive&#8217;s position.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <!--PROfilePageNumberReset%Num%2%-%-%-->
    <table cellspacing="0" cellpadding="0" id="zf3596d89a0f54568a5658d246fc9c5b7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 63pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Section 2.</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"><u>COMPENSATION</u></div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Section 2.1</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Base Salary</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company shall pay Executive during the Term an annual base salary of $435,000 (as it may increase (but not decrease), the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Base Salary</font>&#8221;) payable in accordance with the payroll practices of the Company, subject to reduction by any amounts received by Executive under any disability
      insurance policy provided by the Company to Executive.&#160; Executive&#8217;s overall compensation, including Base Salary, equity grants, and total bonus, shall be reviewed at least annually by the Board for possible increase.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 2.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Benefits</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">During the Term, Executive shall be entitled to participate in all qualified plans, group medical and disability insurance,
      holidays and other employee benefits which the Company, in its sole discretion, may maintain from time to time for the benefit of its executive employees in general, or, if the Company should discontinue or cause to be discontinued any such benefits,
      then similar benefits, if any, as may be provided by the Company to its employees in general.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 2.3</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Annual Bonus Opportunity</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Commencing with respect to the performance year beginning January 1, 2024, Executive shall be entitled to an annual cash bonus,
      the target of which is forty-five percent (45%) of the Base Salary, which target may increase but shall not decrease, based upon the attainment of certain performance milestones and objectives established by the Board (acting through its Compensation
      Committee) in consultation with the Executive.&#160; The &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Target Bonus</font><font style="font-family: 'Times New Roman'; font-style: italic;">,</font>&#8221; if any (as
      determined in the sole discretion of the Board (acting through its Compensation Committee)), shall be payable no later than March 15 of the year after the year in which the performance relates so long as Executive is employed on December 31 of the
      performance year, except as otherwise specified in Section 3.2.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 2.4</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Expenses</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Executive shall be entitled to receive prompt reimbursement for all reasonable business expenses incurred by Executive in the performance of his
      duties for the Company, as soon as possible after such expenses are submitted, in accordance with the policies and procedures adopted by the Company from time to time for executive officers of the Company, but in no event later than June 30 of the
      year following the year in which the expense was incurred.&#160; Executive shall furnish appropriate documentation of such expenses, including documentation required by the Internal Revenue Service.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">-2-</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 2.5</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Option and Restricted Stock Unit Grants</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Executive has been granted restricted
          stock units for the right to receive shares of common stock, par value $0.0001 per share (the &#8220;Shares&#8221;) of the Company (the &#8220;Restricted Stock Units&#8221;). Notwithstanding anything contained in the restricted stock unit grant agreements, if the
          Executive&#8217;s employment is terminated by the Company or its successor for any reason other than Cause (as defined below) or by the Executive for Good Reason (as defined below) immediately preceding or within one year after a Change of Control (as
          defined below) of the Company, all Shares underlying such Restricted Stock Units, as well as all Shares underlying any other restricted stock units or stock options granted in the future to Executive by the Company, shall be immediately vested
          and in the case of stock options, exercisable, upon such termination of employment and with specific respect to such stock options shall remain exercisable until the earlier of one and one-half (1.5) years after the Executive&#8217;s termination of
          employment or the expiration of the ten-year term of the options.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160; &#160; &#160; <font style="font-family: 'Times New Roman';">For purposes of this
          Agreement, &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Change of Control</font>&#8221; means the occurrence, in a single transaction or in a series of related transactions, of any one or more of the following
          events:</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; text-indent: 27pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(i)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman';">any person or group
          (within the meaning of Section 13(d) or 14(d) of the Securities Exchange Act of 1934, as amended) that is not an Affiliate (as defined below) becomes the owner, directly or indirectly, of voting securities of the Company representing fifty
          percent (50%) or more of the combined voting power of the Company&#8217;s then outstanding voting securities other than by virtue of a merger, consolidation or similar transaction;</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; text-indent: 27pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(ii)</font><font style="font-size: 10pt;">&#160; &#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman';">there is consummated
          a merger, consolidation or similar transaction including a sale of substantially all of the assets of the Company involving (directly or indirectly) the Company if, immediately after the consummation of such merger, consolidation or similar
          transaction, the stockholders of the Company immediately prior thereto do not own, directly or indirectly, either (A) outstanding voting securities representing more than fifty percent (50%) of the combined outstanding voting power of the
          surviving entity in such merger, consolidation or similar transaction or (B) more than fifty percent (50%) of the combined outstanding voting power of the parent of the surviving entity in such merger, consolidation or similar transaction; or</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; text-indent: 27pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(iii)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">any person or group
          (within the meaning of Section 13(d) or 14(d) of the Securities Exchange Act of 1934, as amended) that is not an Affiliate acquires by sale, lease, license or other transaction all or substantially all of the consolidated assets of the Company;
          or</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; margin-left: 36pt; text-indent: 27pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(iv)&#160;</font><font style="font-size: 10pt;"> &#160;&#160;&#160; <font style="font-family: 'Times New Roman';">during any consecutive
          twelve-month period, the following individuals cease for any reason to constitute a majority of the number of directors then serving: individuals who, on the date hereof, constitute the Board and any new director (other than a director whose
          initial assumption of office is in connection with an actual or threatened election contest, including but not limited to a consent solicitation, relating to the election of directors of the Company) whose appointment or election by the Board or
          nomination for election by the Company&#8217;s stockholders was approved or recommended by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors on the date hereof or whose appointment, election or
          nomination for election was previously so approved or recommended;</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">-3-</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-style: italic;">provided, however</font><font style="font-size: 10pt;">, that solely for purposes of
        Section 3.2(b)(i) and 3.2(b)(ii), (x) such transaction or series of transactions shall not constitute a Change of Control unless a person or group acquires &#8220;more than fifty percent (50%)&#8221; of combined voting power of the Company and (y) no such
        transaction or series of related transactions shall constitute a Change of Control under any clause under this subsection (b) unless such transaction or transaction also qualifies as a change in ownership or control of the Company within the
        meaning of Treasury Regulation Section 1.409A-3(i)(5)(v) or (vi) or a change in ownership of a substantial portion of the Company&#8217;s assets within the meaning of Treasury Regulation Section 1.409A-3(i)(5)(vii).&#160; For purposes of this Agreement, &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Affiliate</font>&#8221; means, with respect to any Person, any other Person directly or indirectly controlling, controlled by or under common control with, such Person.&#160;&#160;
        For purposes of this definition, &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">control</font>&#8221; (including with correlative meanings, the terms &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">controlling</font>&#8221;, &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">controlled by</font>&#8221; or &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">under
          common control with</font>&#8221;), as used with respect to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such person, whether through the ownership of voting
        securities or by contract or otherwise, and &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Person</font>&#8221; means an individual, a partnership, a joint venture, a corporation, an association, a trust, an estate
        or other entity or organization, including a government or any department or agency thereof.</font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">I</font>n consideration of the Executive&#8217;s entering into this Agreement, on the Effective Date, Executive shall be granted an option to purchase 115,100 shares, which shall vest over
          four years with 25% of the Shares underlying the option vesting on the one-year anniversary of the Effective Date and the remaining 75% of such Shares vesting monthly in equal installments over the next three years, becoming fully vested on the
          four-year anniversary of the Effective Date, and 72,400 Restricted Stock Units, which shall vest in four equal annual installments (25% per installment) on each anniversary of the Effective Date over four years, in each case under the ADMA
          Biologics, Inc. 2022 Equity Compensation Plan (the &#8220;Plan&#8221;).&#160; For sake of clarity, and notwithstanding anything to the contrary in Section 8(c) of the Plan, any Restricted Stock Units which vest prior to the date Executive ceases to be employed
          by, or provide service to the Company, shall not be subject to forfeiture.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z8b17f00a6f2f4b958fec641f2e9edb57" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 63pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Section 3.</td>
          <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"><u>TERMINATION OF EMPLOYMENT</u></div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Section 3.1</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Termination by the Company</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160; &#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Death</u></font>.&#160; Executive&#8217;s employment pursuant to this Agreement shall terminate upon Executive&#8217;s death.&#160; In such event any amounts payable to Executive pursuant to Section 3.2 shall be paid directly to Executive&#8217;s estate.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160; &#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Disability</u></font>.&#160; In the event that Executive is, because of a Disability (as defined below), incapable of performing his duties hereunder, the Company shall have the right to terminate Executive&#8217;s employment hereunder upon
          written notice to Executive.&#160; &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Disability</font>&#8221; or &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Disabled</font>&#8221; shall
          mean any physical or mental ailment or incapacity as determined by a licensed physician agreed to by the Company and Executive (or in the event that Executive and the Company cannot so agree, by a licensed physician agreed upon by a physician
          selected by Executive and a physician selected by the Company), which prevents Executive from performing the duties incident to Executive&#8217;s employment hereunder which has continued for a period of either (i) one hundred eighty (180) consecutive
          days in any 12-month period or (ii) one hundred eighty (180) total days in any 12-month period, and which can reasonably be expected to be of a permanent duration, or is expected to result in death.&#160; Executive shall permit such physician to
          examine Executive from time to time prior to Executive being determined to be Disabled, as reasonably requested by the Company, to determine whether Executive has suffered a Disability hereunder.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">-4-</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-size: 10pt;">&#160;&#160; &#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Breach of Agreement</u></font>.&#160; In the event that Executive materially breaches, or fails to comply with, any of the provisions of this Agreement, the Company shall have the right to terminate Executive&#8217;s employment hereunder (i)
          if upon notice from the Company, Executive fails, in the reasonable judgment of the Board, to cure such breach or failure to comply, if curable, within 30 days, and (ii) immediately upon notice to Executive if the termination is for Cause (as
          defined below) and if such breach or failure to comply cannot be cured ,in the reasonable judgment of the Board.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Cause</u></font>.&#160; The Company shall have the right to terminate Executive&#8217;s employment hereunder for cause.&#160; The term &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Cause</font>&#8221; shall mean:&#160;
          (i) dishonesty, fraud, or any act involving moral turpitude, which results, or is reasonably likely to result in material harm to the Company, (ii) willful disobedience or insubordination, which results, or is reasonably likely to result, in
          material harm to the Company, (iii) intentional or gross neglect of the performance of his duties as set forth herein, (iv) intentional withholding or nondisclosure of material information to the Company, (v) acting for a party whose interests
          are known to the Executive to be adverse to the Company, which results, or is reasonably likely to result in material harm to the Company, or (vi) being convicted of a felony.&#160; If such alleged event of Cause is susceptible to cure, the Company
          shall provide 30 days written notice and may only terminate for Cause if Executive has failed to cure or take reasonable steps to cure such alleged event of Cause, provided, however, that such reasonable steps, which are taken within 30 days of
          notice, leads to a cure within no more than 60 days.&#160; To terminate Executive&#8217;s employment for &#8220;Cause&#8221; (i) the Company must provide Executive with a termination notice that (a) states that Executive is being terminated for Cause, (b) indicates the
          subsection above that the Company is relying on, and (c) provides reasonable detail of the facts providing the basis for that reliance; and (ii) the Company must provide Executive with a right to be heard by the Board, with his counsel present if
          he so elects, before taking such action to terminate his employment.&#160; For purposes hereof, no act shall be deemed &#8220;willful&#8221; or &#8220;intentional&#8217; unless done, or omitted to be done, in bad faith or not in the best interests of the stockholders.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Involuntary Termination</u></font>. The Company shall have the right to terminate Executive&#8217;s employment hereunder, and Executive shall have the right to resign at any time, for any reason or for no stated reason.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 3.2</font><font style="font-size: 10pt;">&#160;&#160;&#160; &#160; &#160; &#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Rights of Executive Upon Termination</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">In the event that
          Executive&#8217;s employment is terminated (i) pursuant to Sections 3.1(a) or (b), (ii) by the Company pursuant to Section 3.1(c), (iii) by the Company with Cause pursuant to Section 3.1(d) or (iv) due to a resignation by Executive pursuant to Section
          3.1(e) without Good Reason (as defined), the Company shall have no further obligation to Executive under this Agreement except for payment to Executive of (A) his accrued, but unpaid Base Salary through the date of termination, (B) any
          unreimbursed expenses, subject to any right of set-off, and (c) if terminated pursuant to Sections 3.1(a) or (b), the Company will reimburse Executive (or his qualified beneficiaries) for the same portion of Executive&#8217;s family COBRA health
          insurance premium (if continued coverage under COBRA is elected) and COBRA dental and vision premiums (if available under COBRA), that it paid during the Executive&#8217;s employment for at least twelve (12) months after the date of Executive&#8217;s
          termination and the Executive or his estate shall be entitled to any unpaid annual bonus from any prior performance year.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">-5-</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">In the event that
          Executive&#8217;s employment is terminated (i) by the Company pursuant to Section 3.1(e) without Cause, (ii) due to a resignation by Executive pursuant to Section 3.4 for Good Reason or (iii) any termination resulting from a Change of Control in which
          this Agreement is not assumed by the successor to the Company (if assumption is required for this Agreement to be binding upon such successor), the Company shall have no further obligation to Executive under this Agreement except for payment to
          Executive of (A) his accrued, but unpaid Base Salary through the date of termination, (B) any unreimbursed expenses, subject to any right of set-off, (C) in the event the Executive elects continued coverage under COBRA, the Company will reimburse
          Executive for the same portion of Executive&#8217;s family COBRA health insurance premium that it paid during the Executive&#8217;s employment up until the earlier of (i) the date twelve (12) months after the date of Executive&#8217;s termination and (ii) the date
          on which the Executive is eligible for comparable health benefits with another company or business entity; provided, however, that in the event Executive&#8217;s employment is terminated for the reasons stated above in this Section 3.2(b) immediately
          preceding or within one year following a Change of Control (including, without limitation, the failure of a successor to assume), the Company will reimburse Executive for the same portion of Executive&#8217;s family COBRA health insurance premium that
          it paid during the Executive&#8217;s employment up until the earlier of (i) the date twelve (12) months after the date of Executive&#8217;s termination and (ii) the date on which the Executive is eligible for comparable health benefits with another company
          or business entity, (D) any Target Bonus that has not been paid from the prior performance year to the extent the Board of Directors has determined in good faith that the goals have been attained, payable within 30 days of the date of
          termination, (E) a severance payment equal to twelve (12) months Base Salary payable in twelve (12) monthly, equal installments after termination; provided however, that in the event Executive&#8217;s employment is terminated for the reasons stated
          above in this Section 3.2(b) immediately preceding or within one year following a Change of Control (including, without limitation, the failure of a successor to assume), such severance payment will be equal to fifteen (15) months Base Salary
          plus one and one half (1.5) times the annual Target Bonus, payable in a lump sum within five business days of his termination, and (F) the accelerated vesting of the Shares underlying stock options and Restricted Stock Units as provided under
          Section 2.5, as applicable.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 3.3</font><font style="font-size: 10pt;">&#160;&#160; &#160; &#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Obligations of Executive Following Termination</u></font>.&#160; In the event that Executive&#8217;s employment is terminated pursuant to Section 3.1, Executive shall have no further obligations hereunder, except
          that if Executive&#8217;s employment was terminated under Section 3.1(c), (d) or (e), he shall (i) provide reasonable cooperation to the Company without charge to the Company (but subject to reimbursement by the Company of any reasonable out-of-pocket
          costs incurred by Executive in the course of such cooperation and obligations he may have to a subsequent employer) as to matters within Executive&#8217;s personal knowledge, and (ii) remain obligated pursuant to Section 4.&#160; For the avoidance of doubt,
          &#8220;reasonable cooperation&#8221; (i) shall mean that (a) it shall not unreasonably interfere with Executive&#8217;s then current employment or business activities, (b) it will not extend beyond 12 months following Executive&#8217;s date of termination of employment,
          and (ii) shall not be required by Executive if his engaging in such cooperation would be against Executive&#8217;s best interests or otherwise be a conflict for Executive (which would include, among other things, having to act in respect of any matter
          that would be adverse to Executive&#8217;s then current employer).</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">-6-</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 3.4</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Good Reason; Notice of Termination</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Resignation for &#8220;Good Reason&#8221; shall mean
          resignation by Executive from his employment hereunder following (i) a material breach by the Company of any of the terms and provisions of this Agreement, (ii) a diminution in Executive&#8217;s title, authority, duties or responsibilities from title,
          authority, duty or responsibilities consistent with the positions of Chief Financial Officer and Treasurer of the Company (which, for the sake of clarity, shall include Executive no longer serving as Chief Financial Officer or Treasurer of the
          Company or reporting directly to the President and Chief Executive Officer, or (iii) the relocation of the Executive&#8217;s principal place of business (i.e., Boca Raton, Florida) by more than twenty (20) miles without the written consent of
          Executive.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160; &#160; <font style="font-family: 'Times New Roman';">The date of termination of employment
          without Cause shall be the date specified in a written notice of termination from the Company to Executive.&#160; Resignation by Executive for Good Reason shall be communicated by delivery to the Company of a written notice from Executive stating that
          Executive shall resign for Good Reason, stating the particulars thereof, and the effective date of the resignation being no later than 180 days from the date of the delivery of the notice (and no sooner than 30 business days).&#160; The Company shall
          have 30 days from the receipt of such notice to effect a cure of the actions or conditions constituting Good Reason, if and to the extent that such actions or conditions are subject to cure in the reasonable judgment of the Board.&#160; Upon a cure or
          correction thereof by the Company, such actions shall no longer constitute Good Reason for purposes of this Agreement.&#160; Notwithstanding the foregoing, an event or condition shall not constitute Good Reason for purposes of this Agreement unless
          Executive terminates his employment as a result of such event or condition no later than one year after the initial occurrence of such event or condition.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z45145240b5134ff98cc4da65679d26da" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 63pt; vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt;">Section 4.</td>
          <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
            <div style="font-family: 'Times New Roman';"><u>COVENANTS</u></div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: left; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Section 4.1</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Restrictive Covenants</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Non-Competition</u></font>.&#160; Executive absolutely and unconditionally covenants and agrees that for the period commencing on the Effective Date of this Agreement, and continuing during his employment with the Company and for a
          period of 9 months thereafter (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Restrictive Period</font>&#8221;), Executive will not, either directly or indirectly, solely or jointly with any other person or
          persons, as an employee, consultant or advisor, or as an individual proprietor, partner, stockholder, director, officer, joint venturer, investor, lender or in any other capacity (whether or not engaged in business for profit), engage or
          participate in a Competing Business.&#160; Nothing herein contained shall, however, prohibit Executive&#8217;s acquisition or ownership of (i) stock or securities listed on a national or regional securities exchange or the Nasdaq Stock Market, so long as
          such investments, in the aggregate, in any particular business enterprise constitute less than five percent (5%) of the total issued and outstanding stock and securities of such enterprise or (ii) passive investment in units or other interests in
          private equity or hedge funds to similar investment vehicles.&#160; The term &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Competing Business</font>&#8221; means (i) the manufacture and sale of IGIV and hyperimmune
          IG, (ii) plasma collection, (iii) the manufacture of plasma products competitive with products manufactured by or under development by the Company, (iv) the manufacture of vaccines to stimulate hyperimmune donors, and (v) any other specific
          business being conducted by the Company during the Term.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">-7-</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Non-Solicitation</u></font>.&#160; Executive absolutely and unconditionally covenants and agrees that during the Restrictive Period, Executive will not, either directly or indirectly, for any reason, whether for Executive&#8217;s own account
          or for the account of any other person, natural or legal, without the prior written consent of the Company: (i) solicit, employ, deal with or otherwise interfere with any contract or relationship of the Company with any employee, officer,
          director or any independent contractor of the Company, while such person or entity is employed by or associated with the Company or in the case of former employees within one year of the termination of such person&#8217;s employment with the Company
          during the Restrictive Period, unless such person was terminated without cause by the Company, (ii) solicit, accept, deal with or otherwise interfere with any contract or relationship of the Company with any independent contractor, customer,
          client or supplier of the Company or with any person, natural or legal the effect of which would have an adverse effect on the Company, or (iii) solicit or otherwise interfere with any existing or proposed contract between the Company and any
          other person, natural or legal.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Use and Treatment of Confidential Information</u></font>.&#160; Executive agrees not to disclose, divulge, publish, communicate, publicize, disseminate or otherwise reveal, either directly or indirectly, any Confidential Information to
          any person, natural or legal who is not affiliated with the Company (i.e., employees, stockholders and directors), otherwise bound by an agreement with the Company or obligation of confidentiality for the benefit of the Company or in need of such
          information in connection with services to be provided for the benefit of the Company.&#160; The term &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Confidential Information</font>&#8221; means all information in any
          form relating to the past, present or future business affairs, including without limitation, research, development or business plans, operations or systems, of the Company or a person not a party to this Agreement whose information the Company
          has in its possession under obligations of confidentiality, which is disclosed by the Company to Executive or which is produced or developed while Executive is an owner of, employee or director of the Company.&#160; The term &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Confidential Information</font>&#8221; shall not include any information of the Company which (i) becomes publicly known through no wrongful act of Executive, (ii) is received from a person
          not a party to this Agreement who is free to disclose it to Executive, or (iii) is lawfully permitted or required to be disclosed to any governmental agency or is otherwise required to be disclosed by law, subpoena or court order but only to the
          extent of such requirement, <font style="font-family: 'Times New Roman'; font-style: italic;">provided however</font>, that before making such disclosure Executive shall give the Company, to the extent reasonably possible, an adequate
          opportunity to interpose an objection or take action to assure confidential handling of such information.&#160; Notwithstanding the foregoing, Executive may disclose Confidential Information without violating this Section 4.1(c) to the extent
          reasonably necessary in any dispute proceeding involving Executive&#8217;s right to enforce the terms of this Agreement.&#160; Executive (i) may make and retain electronic copies of his contact list and calendar without violating this Section 4(c) and (ii)
          may retain any documentation relevant to and reasonably necessary to file his income tax returns, in each case.&#160; This Agreement also is not intended to, and shall not in any way prohibit, limit or otherwise interfere with the Executive&#8217;s
          protected rights under federal, state or local law to without notice to the Company: (i) communicate or file a charge with a government regulator; (ii) participate in an investigation or proceeding conducted by a government regulator; or (iii)
          receive an award paid by a government regulator for providing information.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">-8-</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Ownership and Return of Confidential Information</u></font>.&#160; All Confidential Information disclosed to or obtained by Executive in tangible form (including, without limitation, information incorporated in computer software or held
          in electronic storage media) shall be and remain the property of the Company.&#160; All Confidential Information possessed by Executive at the time he ceases employment with the Company shall be returned to the Company at such time.&#160; Upon the return
          of Confidential Information, it shall not thereafter be retained in any form, in whole or in part, by Executive.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160; &#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Work Product Assignment</u></font>.&#160; Executive hereby assigns to the Company all of his right, title and interest in and to, and shall disclose promptly to the Company, any and all work product, developments, processes, inventions,
          ideas and discoveries, and works of authorship developed, discovered, improved, authored, derived, invented or acquired by Executive during the period of her employment by the Company (collectively, &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Work Product</font>&#8221;), whether or not during business hours, that are either related to the scope of Executive&#8217;s employment by the Company or make use, in any manner, to the dedicated resources of the
          Company, and agrees that such Work Product shall be and shall remain the exclusive property of the Company.&#160; The parties hereto understand that the term Work Product includes, but is not limited to, all work product developed, discovered,
          improved, authored, derived, invented or acquired by Executive that:&#160; (i) incorporates or reflects any Confidential information, (ii) relates to the business of the Company or the Company&#8217;s actual or anticipated research and development with
          respect to Confidential Information, or (iii) results from any work performed by Executive for the Company.&#160; Work Product shall not include anything relating to a potential transaction or matter which involves the business of the Company as then
          conducted (or is related thereto, or a business the Company is then contemplating entering) and may be an investment or business opportunity or of prospective economic or competitive advantage to the Company, with respect to which the Board has
          made a determination not to pursue.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(f)</font><font style="font-size: 10pt;">&#160; &#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Remedies upon Breach</u></font>.&#160; The parties acknowledge that Confidential Information and the other protections afforded to the Company by this Agreement are valuable and unique and that any breach of any of the covenants
          contained in this Section 4.1 will result in irreparable and substantial injury to the Company for which it will not have an adequate remedy at law.&#160; In the event of a breach or threatened breach of any of the covenants contained in this Section
          4.1, the Company may seek from any court having jurisdiction, with respect to Executive, temporary, preliminary and permanent injunctive relief prohibiting any such breach, as well reimbursement for all reasonable costs, including attorneys&#8217;
          fees, incurred in enjoining any such breach (if the Company is successful in getting injunctive relief; <font style="font-family: 'Times New Roman'; font-style: italic;">provided however</font>, that in the event that Company is not successful
          it shall reimburse Executive for his reasonable costs, including attorneys&#8217; fees, related thereto).&#160; Any such relief shall be in addition to and not in lieu of any appropriate relief in the way of monetary damages and equitable accounting of all
          earnings, profits and other benefits arising from such violation, which rights shall be cumulative and in addition to any other rights or remedies to which the Company may be entitled.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">-9-</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Section 4.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Non-Disparagement</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">During the Term, and thereafter, (i) Executive agrees not to defame, disparage or criticize the Company, its business plan, procedures, products,
      services, development, finances, financial condition, capabilities or other aspect of its business, or any of its stockholders in any medium (whether oral, written, electronic or otherwise, whether currently existing or hereafter created), to any
      person or entity not affiliated with the Company, without limitation in time, and (ii) Company agrees not to defame, disparage or criticize Executive in any medium (whether oral, written, electronic or otherwise, whether currently existing or
      hereafter created), to any person or entity not affiliated with the Company, without limitation in time.&#160; Notwithstanding the foregoing sentence, the Company and Executive may confer in confidence with its/his advisors and make truthful statements as
      required by law.&#160; This Section 4.2 shall survive any termination of Executive&#8217;s employment and any termination of this Agreement.&#160; The Company shall request that each executive of the Company who enters into an employment agreement be similarly
      bound.&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Notwithstanding the foregoing, this Section 4.2 shall not apply to truthful </font>statements made in the course of sworn testimony in administrative, judicial or arbitral
      proceedings or normal competitive statements.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Section 4.3</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>No Other Severance Benefits</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Except as specifically set forth in this Agreement, Executive covenants and agrees that he shall not be entitled to any other form of severance
      benefits from the Company, including, without limitation, benefits otherwise payable under any of the Company&#8217;s regular severance policies, in the event her employment hereunder ends for any reason and, except with respect to obligations of the
      Company expressly provided for herein, upon payment of any severance payable to Executive hereunder, as a condition to receiving any severance payable to Executive hereunder, Executive unconditionally releases the Company and its subsidiaries and
      affiliates, and their respective directors, officers, employees and stockholders, or any of them, from any and all claims, liabilities or obligations under any severance or termination arrangements of the Company or any of its subsidiaries or
      affiliates other than (i) rights to enforce the terms of this Agreement that are intended to survive its termination, including, without limitation, Section 3.2 and 12.6 and (ii) vested rights under any other employee benefit plan,&#160; rights to
      indemnification under this Agreement and any other Indemnification Agreement, and rights with respect to stock options or other equity awards.&#160; The Company shall provide Executive such release no later than three days following Executive&#8217;s
      termination of employment, which will require that Executive (i) execute and deliver such release to the Company within the time prescribed therein, but in no event later than 50 days after the date of Executive&#8217;s termination of employment, and (ii)
      not revoke such release pursuant to any revocation rights afforded by law.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="zfc034bfbaea54dcaadefa6d3ae8f4cb2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 63pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Section 5.</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"><u>TAX PROVISIONS</u></div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Section 5.1</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Section 409A</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">It is the intention of the parties that
          this Agreement be exempt from or comply with the provisions of Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), and Treasury Regulations and other Internal Revenue Service guidance promulgated thereunder (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Section 409A</font>&#8221;).&#160; Accordingly, this Agreement, including, but not limited to, any provisions relating to severance payments, may be amended from time to time
          as may be necessary or appropriate to comply with Section 409A.&#160; All references hereunder to termination of the Executive&#8217;s employment with the Company shall mean &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">separation from service</font>&#8221; (as such term is defined in Section 409A).&#160; Executive&#8217;s right to receive any installment payments pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct
          payments.&#160; Further, notwithstanding anything else to the contrary in this Agreement, if (i) Executive is entitled to receive payments or benefits under this Agreement by reason of his separation from service other than as a result of his death,
          (ii) Executive is a &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">specified employee</font>&#8221; (within the meaning of Section 409A), for the period in which the payment or benefits would otherwise commence,
          and (iii) such payment or benefit would otherwise subject Executive to any tax, interest or penalty imposed under Section 409A if the payment or benefit would commence within six months of a termination of Executive&#8217;s employment with the Company,
          then such payment or benefit required under this Agreement will not commence until the first day that is at least six months after the termination of Executive&#8217;s employment and such first payment will include all amounts that would have been
          payable if no delay had been required, <a name="z_BPDCI1009"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#160;</font><a name="z_BPDCI1008"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">plus an
            amount (the &#8220;</font><font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic; color: rgb(0, 0, 0);">Delayed Earnings Payment</font><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">&#8221;) equal to the
            greater of (i) interest computed from the date on which each such delayed payment otherwise would have been made to Executive until the date of payment</font><a name="z_BPDCI1007"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">, computed at the </font><a name="z_BPDCI1005"></a><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);">national average annual rate of interest payable on jumbo six-month bank certificates of deposit, as quoted in the
            business section of the most recently published Sunday edition of The New York Times preceding Executive&#8217;s separation from service, or (ii) the actual earnings of the rabbi trust established pursuant to Section 5.1(b) below.</font></font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">-10-</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">In the event that Executive is subject to
          the six-month delay referred to above, the Company shall, within five business days of the date of termination, establish an irrevocable grantor trust (a &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">rabbi trust</font>&#8221;),
          appoint a federally or state chartered bank or trust company as the trustee for such rabbi trust and contribute that amount of funds to satisfy the compensation that is payable on the six month anniversary in the rabbi trust.&#160; The needed assets
          of such rabbi trust shall be used solely to make the severance payments (and Delayed Earnings Payment set forth in Section 5.1(a)) to the Executive as required under this Agreement (or to reimburse the Company for severance payments and Delayed
          Earnings Payment it makes to the Executive); or to satisfy the claims of the Company&#8217;s unsecured general creditors in the event of the Company&#8217;s insolvency or bankruptcy.&#160; The rabbi trust may be terminated and any remaining assets therein shall
          revert to the Company after the Executive has received all of the severance payments and Delayed Earnings Payment to which he is entitled hereunder.&#160; Notwithstanding the foregoing, no rabbi trust shall be established if the funding of the rabbi
          trust would subject the Executive to acceleration of taxation and tax penalties under Section 409A(b) of the Code.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">Section 5.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Excess Parachute Excise Tax</u></font>.&#160; Anything in this Agreement to the contrary notwithstanding, in the event it shall be determined that any payment, award, benefit or distribution (including any acceleration) by the
          Company or any entity which effectuates a transaction described in Section 280G(b)(2)(A)(i) of the Code to or for the benefit of the Executive (whether pursuant to the terms of this Agreement or otherwise, but determined before application of any
          reductions required pursuant to this Section 5.2) (a &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Payment</font>&#8221;) would be subject to the excise tax imposed by Section 4999 of the Code or any interest or
          penalties are incurred with respect to such excise tax by the Executive (such excise tax, together with any such interest and penalties, are hereinafter collectively referred to as the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Excise Tax</font>&#8221;), the Company will automatically reduce such Payments to the extent, but only to the extent, necessary so that no portion of the remaining Payments will be subject to the Excise Tax, unless the
          amount of such Payments that the Executive would retain after payment of the Excise Tax and all applicable Federal, state and local income taxes without such reduction would exceed the amount of such Payments that the Executive would retain after
          payment of all applicable Federal, state and local taxes after applying such reduction.&#160; Unless otherwise elected by the Executive, to the extent permitted under Code Section 409A, such reduction shall first be applied to any severance payments
          payable to the Executive under this Agreement, then to the accelerated vesting on any equity awards, starting with stock options and stock appreciation rights reversing accelerated vesting of those options and stock appreciation rights with the
          smallest spread between fair market value and exercise price first and after reversing the accelerated vesting of all stock options and stock appreciation rights, thereafter reversing accelerated vesting of restricted stock, restricted stock
          units and performance shares, performance units or other similar equity awards on a pro rata basis.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">-11-</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">All determinations required to be made under this Section 5.2, including the assumptions to be utilized in arriving at such determination, shall be
      made by the Company&#8217;s independent auditors or such other certified public accounting firm of national standing reasonably acceptable to the Executive as may be designated by the Company (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Accounting Firm</font>&#8221;) which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the receipt of notice from the Executive that there has been a Payment, or
      such earlier time as is requested by either the Company or the Executive.&#160; All fees and expenses of the Accounting Firm shall be borne solely by the Company.&#160; If the Accounting Firm determines that no Excise Tax is payable by the Executive, it shall
      furnish the Executive with a written opinion to such effect.&#160; Any determination by the Accounting Firm shall be binding upon the Company and the Executive.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" id="z7dec3605cf2042e6ad038dd5d0ee8184" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

        <tr>
          <td style="width: 63pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Section 6.</td>
          <td style="width: auto; vertical-align: top; text-align: justify; font-size: 10pt;">
            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman';"><u>GENERAL PROVISIONS</u></div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 6.1</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Notice</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Any notice required or permitted hereunder shall be given in writing and shall be deemed effectively given upon the earliest of (i) personal delivery,
      (ii) actual receipt, or (iii) overnight mail, next day delivery, by FedEx (or another reputable courier) addressed to the Company at its principal offices, to the attention of the Board with a copy to the Secretary, or, if to Executive, to such home
      or other address as Executive has most recently provided in writing to the Company.&#160; The parties also agree, in addition, to provide a copy of such communication via email, as an additional courtesy copy which, in and of itself, shall not constitute
      notice.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 6.2</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Assignment; Binding Effect</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Neither Executive nor the Company may assign this Agreement without the prior written consent of the other party, except that the
      Company may assign this Agreement to any affiliate thereof, or to any subsequent purchaser of the Company or all or substantially all of the assets of the Company, or by operation of law.&#160; This Agreement shall automatically be deemed assigned to an
      acquirer in the event of a Change of Control.&#160; This Agreement shall be binding upon the heirs, executors, and administrators of Executive.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 6.3</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Choice of Law; Consent to Jurisdiction; Waiver of Jury Trial</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">THIS AGREEMENT SHALL BE GOVERNED BY, CONSTRUED IN ACCORDANCE WITH AND ENFORCED UNDER THE LAWS OF THE STATE OF NEW JERSEY.&#160; ALL
      SUITS, ACTIONS OR PROCEEDINGS ARISING OUT OF OR RELATING TO THIS AGREEMENT, SHALL BE BROUGHT IN A STATE OR FEDERAL COURT LOCATED IN THE STATE OF NEW JERSEY, WHICH COURTS SHALL BE THE EXCLUSIVE FORUM FOR ALL SUCH SUITS, ACTIONS OR PROCEEDINGS.&#160;
      EXECUTIVE AND THE COMPANY HEREBY WAIVE ANY OBJECTION WHICH HE OR IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE IN ANY SUCH COURT OR ANY SUCH SUIT, ACTION OR PROCEEDING.&#160; EXECUTIVE AND THE COMPANY HEREBY IRREVOCABLY CONSENT AND SUBMIT THEMSELVES
      TO THE JURISDICTION OF THE COURTS OF THE STATE OF NEW JERSEY FOR THE PURPOSES OF ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF THIS AGREEMENT.&#160; EXECUTIVE AND THE COMPANY HEREBY WAIVE ANY RIGHT TO A TRIAL BY JURY IN ANY SUIT, ACTION OR PROCEEDING
      ARISING OUT OF OR RELATING TO THIS AGREEMENT AND AGREE THAT ANY SUCH SUIT, ACTION OR PROCEEDING SHALL BE TRIED BEFORE A COURT AND NOT BEFORE A JURY.&#160; EXECUTIVE SHALL BE REIMBURSED FOR HIS REASONABLY INCURRED LEGAL FEES AND EXPENSES IF HE PREVAILS ON
      ANY MATERIAL ISSUE WHICH IS A SUBJECT OF SUCH SUIT, ACTION OR PROCEEDING.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">-12-</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 6.4</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Amendment; Waiver</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">No modification, amendment or termination of this Agreement shall be valid unless made in writing and signed by the parties
      hereto, and approved by the Board (but not including Executive).&#160; Any waiver by any party of any violation of, breach of or default under any provision of this Agreement, by the other party shall not be construed as, or constitute, a continuing
      waiver of such provision, or waiver of any other violation of breach of or default under any other provision of this Agreement.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 6.5</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Withholding of Taxes</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The Company may withhold from any amounts payable under this Agreement all federal, state, city or other taxes as shall be
      required to be withheld pursuant to any law or government regulation or ruling.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 6.6</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Severability</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Any provision of this Agreement which is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be
      ineffective to the extent possible without invalidating the remaining provisions hereof or affecting the validity or enforceability of such provision in any other jurisdiction.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 6.7</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Survival of Certain Obligations</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The obligations of the Company and Executive set forth in this Agreement which by their terms extend beyond or survive the
      termination of the Term shall not be affected or diminished in any way by the termination of the Term.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 6.8</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Headings</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">The headings in this Agreement are intended solely for convenience and shall be disregarded in interpreting it.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">-13-</font></div>
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 6.9</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Entire Agreement</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">On the Effective Date, this Agreement sets forth the entire understanding of the parties to this Agreement regarding the subject matter hereof and
      supersedes all prior agreements, arrangements, communications, representations and warranties, whether oral or written, between the parties regarding the subject matter hereof.&#160;&#160; Any prior employment or similar agreement between Executive and the
      Company (or any subsidiary thereof) (each, a &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold; font-style: italic;">Prior Agreement</font>&#8221;), whether written or oral, shall be null and void from and after the Effective Date of this
      Agreement and Executive shall not be entitled to any rights or remedies under, or payment of any amounts pursuant to, any Prior Agreements, and neither the Company nor any subsidiary shall have any further obligation to Executive under any Prior
      Agreements.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 6.10</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Third Parties</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">Nothing expressed or implied in this Agreement is intended, or shall be construed, to confer upon or give any person or entity
      other than the Company and Executive any rights or remedies under, or by reason of, this Agreement.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 6.11</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Attorney Fees</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company agrees to pay or reimburse Executive&#8217;s legal fees incurred in connection with the negotiation and review of this Employment Agreement in
      an amount up to $10,000, which shall be paid within 30 days of the Company&#8217;s receipt of an invoice.&#160; All reasonable legal fees paid or incurred by Executive in any litigation or dispute to enforce Executive&#8217;s rights hereunder shall be paid or
      reimbursed by the Company if Executive is the prevailing party in such litigation or dispute.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 6.12</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><u>Indemnification</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">The Company shall, to the maximum extent permitted by law, indemnify and hold Executive harmless against, and shall purchase director and officer
      indemnity insurance on behalf of Executive for, expenses, including reasonable attorney&#8217;s fees (the attorney to be selected by Executive, but subject to the consent of the Company which shall not unreasonably be withheld or delayed), judgments,
      fines, settlements and other amounts actually and reasonably incurred in connection with any proceeding or claim (or threatened proceeding or claim) arising by reason of Executive&#8217;s employment by, or service as a member of the Board of, the Company.&#160;
      The Company shall advance to Executive any expense incurred in defending any such proceeding or claim (or threatened proceeding or claim) to the maximum extent permitted by law.&#160; This section shall be read in conjunction with the Indemnification
      Agreement between the parties and to the extent there is any conflict between said agreements, the Executive shall be entitled to the maximum level of indemnification by the Company.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">Section 6.13</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman'; color: rgb(0, 0, 0);"><font style="font-family: 'Times New Roman';"><u>Counterparts</u></font>.</font></font></div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">This Agreement may be executed in counterparts, and all of such counterparts (including facsimile or PDF), when separate
      counterparts have been executed by the parties hereto, shall be deemed to be one and the same agreement.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div style="text-align: center; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">[<font style="font-family: 'Times New Roman'; font-style: italic;">Signature Page Follows</font>]</div>
    <div style="font-size: 10pt;">&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">-14-</font></div>
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
    </div>
    <div style="text-align: justify; text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;">IN WITNESS WHEREOF, the Company and Executive have executed this Employment Agreement as of the date first written above.</div>
    <div style="font-size: 10pt;">&#160;</div>
    <table cellspacing="0" cellpadding="0" border="0" id="zb8d4833832724548bd5511c2f36195f4" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="2">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">ADMA BIOLOGICS, INC.</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: top; border-bottom: 2px solid black; font-size: 10pt;" colspan="2">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">/s/ Adam S. Grossman</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">By:</div>
          </td>
          <td style="width: 45%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Adam S. Grossman</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="width: 5%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">Title:</div>
          </td>
          <td style="width: 45%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">President and Chief Executive Officer</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="2">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-weight: bold;">EXECUTIVE</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: top; font-size: 10pt;" colspan="2">&#160;</td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: top; border-bottom: 2px solid black; font-size: 10pt;" colspan="2">
            <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman';">/s/ Brad Tade</div>
          </td>
        </tr>
        <tr>
          <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
          <td style="vertical-align: top;" colspan="2">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0);">By: </font><font style="font-size: 10pt;">Brad Tade</font></div>
          </td>
        </tr>

    </table>
    <div style="font-size: 10pt;"><br>
    </div>
    <div style="font-size: 10pt;">&#160;<br>
      <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
  </div>
  <font style="font-size: 10pt;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>adma-20240724.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.6.1.5240 Broadridge-->
<xs:schema targetNamespace="http://admabiologics.com/20240724" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:adma="http://admabiologics.com/20240724" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-types="http://fasb.org/srt-types/2023">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20240724_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20240724_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://admabiologics.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2023" schemaLocation="https://xbrl.sec.gov/country/2023/country-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2023" schemaLocation="https://xbrl.sec.gov/exch/2023/exch-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2023" schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2023" schemaLocation="https://xbrl.sec.gov/sic/2023/sic-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>adma-20240724_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.6.1.5240 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:label xlink:type="resource" xlink:label="dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_WrittenCommunications" xml:lang="en-US" id="dei_WrittenCommunications">Written Communications</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WrittenCommunications" xlink:to="dei_WrittenCommunications" xlink:title="label: WrittenCommunications to dei_WrittenCommunications" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:label xlink:type="resource" xlink:label="dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SolicitingMaterial" xml:lang="en-US" id="dei_SolicitingMaterial">Soliciting Material</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SolicitingMaterial" xlink:to="dei_SolicitingMaterial" xlink:title="label: SolicitingMaterial to dei_SolicitingMaterial" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementTenderOffer" xml:lang="en-US" id="dei_PreCommencementTenderOffer">Pre-commencement Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer" xlink:title="label: PreCommencementTenderOffer to dei_PreCommencementTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:label xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_PreCommencementIssuerTenderOffer" xml:lang="en-US" id="dei_PreCommencementIssuerTenderOffer">Pre-commencement Issuer Tender Offer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer" xlink:title="label: PreCommencementIssuerTenderOffer to dei_PreCommencementIssuerTenderOffer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine2" xml:lang="en-US" id="dei_EntityAddressAddressLine2">Entity Address, Address Line Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2" xlink:title="label: EntityAddressAddressLine2 to dei_EntityAddressAddressLine2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine3" xml:lang="en-US" id="dei_EntityAddressAddressLine3">Entity Address, Address Line Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3" xlink:title="label: EntityAddressAddressLine3 to dei_EntityAddressAddressLine3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCountry" xml:lang="en-US" id="dei_EntityAddressCountry">Entity Address, Country</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCountry" xlink:to="dei_EntityAddressCountry" xlink:title="label: EntityAddressCountry to dei_EntityAddressCountry" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:label xlink:type="resource" xlink:label="dei_NoTradingSymbolFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_NoTradingSymbolFlag" xml:lang="en-US" id="dei_NoTradingSymbolFlag">No Trading Symbol Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag" xlink:title="label: NoTradingSymbolFlag to dei_NoTradingSymbolFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>adma-20240724_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 24.6.1.5240 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://admabiologics.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="adma-20240724.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentType" xlink:title="presentation: CoverAbstract to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="AmendmentFlag" xlink:title="presentation: CoverAbstract to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: CoverAbstract to DocumentPeriodEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalYearFocus" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: CoverAbstract to DocumentFiscalPeriodFocus" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityFileNumber" xlink:title="presentation: CoverAbstract to EntityFileNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityRegistrantName" xlink:title="presentation: CoverAbstract to EntityRegistrantName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityCentralIndexKey" xlink:title="presentation: CoverAbstract to EntityCentralIndexKey" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: CoverAbstract to EntityIncorporationStateCountryCode" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: CoverAbstract to EntityTaxIdentificationNumber" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine1" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="EntityAddressAddressLine2" xlink:title="EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine2" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine2" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:label="EntityAddressAddressLine3" xlink:title="EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressAddressLine3" xlink:title="presentation: CoverAbstract to EntityAddressAddressLine3" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: CoverAbstract to EntityAddressCityOrTown" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: CoverAbstract to EntityAddressStateOrProvince" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCountry" xlink:label="EntityAddressCountry" xlink:title="EntityAddressCountry" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressCountry" xlink:title="presentation: CoverAbstract to EntityAddressCountry" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: CoverAbstract to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="CityAreaCode" xlink:title="presentation: CoverAbstract to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="LocalPhoneNumber" xlink:title="presentation: CoverAbstract to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="Security12bTitle" xlink:title="presentation: CoverAbstract to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="TradingSymbol" xlink:title="presentation: CoverAbstract to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_NoTradingSymbolFlag" xlink:label="NoTradingSymbolFlag" xlink:title="NoTradingSymbolFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="NoTradingSymbolFlag" xlink:title="presentation: CoverAbstract to NoTradingSymbolFlag" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SecurityExchangeName" xlink:title="presentation: CoverAbstract to SecurityExchangeName" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: CoverAbstract to EntityEmergingGrowthCompany" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="WrittenCommunications" xlink:title="WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="WrittenCommunications" xlink:title="presentation: CoverAbstract to WrittenCommunications" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="SolicitingMaterial" xlink:title="SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="SolicitingMaterial" xlink:title="presentation: CoverAbstract to SolicitingMaterial" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="PreCommencementTenderOffer" xlink:title="PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementTenderOffer" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="PreCommencementIssuerTenderOffer" xlink:title="PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="PreCommencementIssuerTenderOffer" xlink:title="presentation: CoverAbstract to PreCommencementIssuerTenderOffer" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm139646173765712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 24, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 24,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36728<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ADMA BIOLOGICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001368514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2590442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">465 State Route 17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ramsey<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07446<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">478-5552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADMA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$
MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7<K_WUE[O)I#-ZG7TZSFN4
M?VFK :?MNYO/D_QSZ.2?IY/734+.<+PL"?'[(UMAAR=N.Q-R.AQG0GS/]O:1
MI24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG LR+7E$8D19_(
M+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(R-^-B/>K;YH]
M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M
MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1CVFS(Z=T)LWH
M,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.FJW"$2M"/F(9
M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+
MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T
M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M#2CN^%/PM3XX)O95YE*^VL$XZCN>)>(Q#XV58/#SQD<\CJT2</R[%W7*9]K
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M>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1'
ML#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,
MJ^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@
M\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^
M\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$
M%     @ \XGZ6)>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M2P$"% ,4    " #SB?I8<M<S[>\    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " #SB?I8F5R<(Q &  "<)P
M$P              @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( /.)^EAO]=415 0  )00   8              " @0X(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " #SB?I8GZ ;\+$"  #B#
M#0              @ &8#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( /.)
M^EB7BKL<P    !,"   +              "  70/  !?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( /.)^E@<.&7J/P$  #P"   /              "  5T0  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #SB?I8)!Z;HJT   #X 0  &@
M            @ ')$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    " #SB?I899!YDAD!  #/ P  $P              @ &N$@  6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #X$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ef20033085_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>adma-20240724.xsd</File>
    <File>adma-20240724_lab.xml</File>
    <File>adma-20240724_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ef20033085_8k.htm">ef20033085_8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20033085_8k.htm": {
   "nsprefix": "adma",
   "nsuri": "http://admabiologics.com/20240724",
   "dts": {
    "schema": {
     "local": [
      "adma-20240724.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/exch/2023/exch-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd",
      "https://xbrl.sec.gov/sic/2023/sic-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "adma-20240724_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adma-20240724_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ef20033085_8k.htm"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 29,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 22
   },
   "report": {
    "R1": {
     "role": "http://admabiologics.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20240724to20240724",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20033085_8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240724to20240724",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20033085_8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001140361-24-034440-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-24-034440-xbrl.zip
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M-%]P<F4N>&ULU5M=;^(X%'U?:?]#EGV&%.ATEJK,B&6F(S1,BPJK_7A9F<2
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M1-8S2*&OP L]Y*4Q%(WX'>GN*]X;E;9@"E*7,%"U=A=32^Q2"JGV>_!JCY*
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MV48O6S(D;/%*UCL)<(&Y.W6_;+6DEJV)+'E:$N#YZ_><[M;+EL$FD)"9I)*
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M1W/L8*#K(WW@;.#EG=Y/J^[]]?!+6\<OT+VKL_,;<G5V>7%U\\5??YGS-*>
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M":503_[D- 70BBZ72FP  Z.B?I,H!UN1K,:_1+C;2GACU)CZ OW2$TK^(;N
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M:-$+4% @9$_,=5B#O^VV>J Z29TRBZ[J%I4QR\GL?*YT69:2"@#KJ852=8@
MW 5]!#N5D^Z)@)U E<0B *'3Z?IJJ:QR-99]%>2)6P5=D#QXF?04%1YN:)0X
MUCN#M!7G#\K($2.8E0T$,PO&'!1V5Y<#^E"*"^+"N4JL6PN\:MUQE0W.Q;(-
M]EKU&23%)HDH@^2S6=W2VQ3=3Y@L84(X$=^_!%P!'"F6:C/E91L87GV?"9H
M9V#G+LY9JB].+.J:7C)_\*WE.N](IB%G]]/0!42M:WU=]@&O/!%?/)L5WPN%
MY[<71]))!%&<32_5K2)"YIJ?+YX_ZP+5IVQVVF+5ZJB/9X]^U56K3Q_ATH"4
MXCZV/?MK;([Z_+,-<"'*T@!?VIC^( <6Z&VG1&]RO,<S;.YXZ#O%'CR&N'#"
MYTF_N>UAG5:O';[C?(/#/Q4%6)&4;#;\):-^]>H!S*!$?BTR"PQ-,TW-&?R'
MW>M:3^]/L]G.(8;?-WOT&Y,[[AQLRZ[EJI#&$G%12T;PL&Y]8[D\?,LM =^
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MTAG8.;GH)T6I-'49R\6C531]JI=?D>(\8 &VD#TBW'Q^)WI$^H5ZQ!=1()X
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MMS##>IOG7YM57A@&9(HTK[4);[[JI1\4GOC."^,-&/5\I:V]>L(=8T6F/I^
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MURZ+P &B$G,W7 O1S4@%XQ.=6":IDXS^ZK*JU:0*>X[6M/0D,A6\MVZ; (T
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M54C)CF[DI.=@7"," /.3E;NR!9[\XK"I=D&;IX)/IX3!'6EL!L8$8WP&A%5
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MP-<;6YDFZ-UKP)R,:DDT)-J2%(\/6NIYD'%A&S?0?&ZC0U7!;  D&;5&M>X
M*[_-Z#2++I78-1C@ZQ8GL"IH:[H:F,!!<2=2U(AN=#Y.DI[_.I.!)K<0-=8W
M/N@9/L&H9Q;:S>F?*@DR<DOEY9AQR"''+YMX3S1&RO.N-6&>*6\!95D;D$4S
M80.KP[MN'6]4<&!13=T25@]ST4)<LKY U]A5&L+V%K$@83_T4/B?34[M*F)]
M;N>.^MVG<H?LJ)=GC:R!=Q&$'/>Q(KGB)I[1-G*+7X8%]I+53'(CA405 LP[
MZ4^DAU(59._;D/H00^9Z@^D0A-?V9P)[APRI@N?)W<Z XXC(B\Z*3V"S8#$X
M4X'ZK$JB]&E)35AIRXGBB23L;.?N#]/:#;8@9"6]_8(Y@Y<"?*]DQ+#SB;MX
M;@PDI=)41(]D N3$Q4[.9ZT60KH3D'?.W*)I6J("7D=@J%1I];UB=.G.OHWO
MSKZO6F2 J1@><HBC2#*(,(54'/[I:)-N/3OQB*IJ)L(&^,O ?3-X'1=OEZ6D
MK]<ZK.,YU;0%H8^+7NPC*#E>!-M-(FK$_:#]5=);CH,7I! C0K1;PPZLCHH;
M3*3$V-\.@"LWQ>B7)S8/)I%FT5V$[Z6G$>W9!;V!!75T;K*#_*3H!+4'=$1@
M7PWI5 ^J0&S2IY#4.XX2@2%Q.^&0UW1CI]]GZO2B=AM\M[P-HN&4['6A\%VD
M%:#04>U9&X]*:@-"B4D(S%[I2CC>>$'I:N7T>V]TLX]&NA)!?4;?I '9"EI[
M:LW:(:(U:,>A?](&@*1_"&/35483=C1,QQ?:U:6T7:VW8M24.7J=NZ?A]%0O
MIJ!5<\D(;QU9PBZ0A \5)*^=O_*4KT:CH17GTL57R^=^GJAXZ]GZ3CS:7-_>
M5,^B9'UK-TEVDG6E=C=VM[_G<R_*YW[V8/.YWPZ.!B=[[_Z&.=US0OWV2.]9
MHO><^=ZBMK.FK,I[DO=]&PTKO]12T&A6E-"F#6.;_FI8+G8RH+)YY.GL#4U<
M#RO"W A?9Z<2?\%P:):65:US;KB*/\ITT9'-5Z/T"$F-$+'M0 82N#DEB4Y
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MC.M)!C_\?U!+ 0(4 Q0    ( /.)^E@ _VO?1P,  $@/   1
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I,C P,S,P.#5?97@Q,"TQ+FAT;5!+!08     !0 % $<!  #-=0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>ef20033085_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="adma-20240724.xsd" xlink:type="simple"/>
    <context id="c20240724to20240724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2024-07-24</startDate>
            <endDate>2024-07-24</endDate>
        </period>
    </context>
    <dei:AmendmentFlag
      contextRef="c20240724to20240724"
      id="Fact_edfc46eeb3c447a49242924b28ef2677">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="c20240724to20240724"
      id="Fact_5c1a15279b7d4929bdbc1be3135768a2">0001368514</dei:EntityCentralIndexKey>
    <dei:DocumentType
      contextRef="c20240724to20240724"
      id="Fact_1ef4e8fd317e4c2682688087f5119158">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="c20240724to20240724"
      id="Fact_dc63f37d317c4e6c934201738b484ecb">2024-07-24</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="c20240724to20240724"
      id="Fact_c8703c5d637e4943b13d343620a1c23b">ADMA BIOLOGICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20240724to20240724"
      id="Fact_c100646f88be4590a9401605ec91a21d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="c20240724to20240724"
      id="Fact_e8ace964bebb4a18adb852d8ae6751c8">001-36728</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20240724to20240724"
      id="Fact_607999d3dd13480785d070450ea7641d">56-2590442</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20240724to20240724"
      id="Fact_3a9f1bc68ee74cab82a0a832327366a8">465 State Route 17</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20240724to20240724"
      id="Fact_b989b2d05f2246889dd92ae418ee706b">Ramsey</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20240724to20240724"
      id="Fact_2dd1b53878d445da8488474f5a63accd">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20240724to20240724"
      id="Fact_cb4f955045f14bbdbb5fbe0035ce95c1">07446</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20240724to20240724"
      id="Fact_d97ec8b141c04247b707a2ab31baa0ab">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20240724to20240724"
      id="Fact_6e8856ba6974423e95f4280f4828d5e6">478-5552</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="c20240724to20240724"
      id="Fact_4090b26ae35a4df7bff0b1916773d9eb">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="c20240724to20240724"
      id="Fact_f98386a0629d4ae7bd42ca009ef7d22b">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="c20240724to20240724"
      id="Fact_e0c6445f485b4993b272a3b63a29a6c8">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="c20240724to20240724"
      id="Fact_1c06d2ef52674734b747a430f87cf158">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="c20240724to20240724"
      id="Fact_43a97ff69a43409e92a425a7f0c81fc6">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20240724to20240724"
      id="Fact_17a93cc70757422db347cd4f1e5c9324">ADMA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20240724to20240724"
      id="Fact_26a7ae3d11b143f29813bc6134b4d9eb">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20240724to20240724"
      id="Fact_7ad0cee0f40b44ed92ebf1abe6c6c856">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
